Last reviewed · How we verify

Efficacy of Botox subdermally at Week 18

ASIS Corporation · Phase 1 active Small molecule

Efficacy of Botox subdermally at Week 18 is a Small molecule drug developed by ASIS Corporation. It is currently in Phase 1 development. Also known as: Botox (onabotulinumtoxinA).

At a glance

Generic nameEfficacy of Botox subdermally at Week 18
Also known asBotox (onabotulinumtoxinA)
SponsorASIS Corporation
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Efficacy of Botox subdermally at Week 18

What is Efficacy of Botox subdermally at Week 18?

Efficacy of Botox subdermally at Week 18 is a Small molecule drug developed by ASIS Corporation.

Who makes Efficacy of Botox subdermally at Week 18?

Efficacy of Botox subdermally at Week 18 is developed by ASIS Corporation (see full ASIS Corporation pipeline at /company/asis-corporation).

Is Efficacy of Botox subdermally at Week 18 also known as anything else?

Efficacy of Botox subdermally at Week 18 is also known as Botox (onabotulinumtoxinA).

What development phase is Efficacy of Botox subdermally at Week 18 in?

Efficacy of Botox subdermally at Week 18 is in Phase 1.

Related